Clavis Pharma appoints chief business officer

Nicholas Adams takes the role at Norwegian firm

Clavis Pharma, a Norwegian cancer drug development company, has appointed Nicholas Adams as chief business officer. He replaces Jan Alfheim, who has become managing director of Nordic Nanovector.

For the past 12 years, Adams worked for the UK cancer company, Antisoma plc, the majority of the time as vice president business development and a member of the senior management team.

Prior to this, he spent 11 years in various positions at Ciba-Geigy (now Novartis), Eisai and Covance.

Olav Hellebø, ceo of Clavis Pharma, said Adams brings to the company considerable experience in business development, particularly in building partnerships with leading pharmaceutical companies, and with a strong focus in oncology.

You may also like

Regulatory
Anticancer agent – elacytarabine

Anticancer agent – elacytarabine

Cytarabine can cross the blood–brain barrier and is useful in the treatment of CNS lymphomas, but the response is variable and resistance commonly develops
Regulatory

Leukaemia treatment gains fast track designation

Clavis Pharma’s elacytarabine currently in Phase III trial
Manufacturing
The 7 most common process development mistakes

The 7 most common process development mistakes

At laboratory scale, processes may appear predictable, repeatable, and well understood. However this perceived level of control can be misleading
Manufacturing
What are injectable hydrogel microspheres?

What are injectable hydrogel microspheres?

The demand for longer-lasting therapies is accelerating innovation in injectable drug delivery, driven by the need to maintain stable therapeutic levels while minimising repeated administration
Regulatory
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS

Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS

The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Research & Development
Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker

Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker

New homogeneous, plate-based assay enables researchers to track hKi-67 in a simple add-and-read format, delivering robust and reproducible results in less time
Research & Development
BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset

BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset

The deal, worth up to $800m including milestones, marks BioArctic's fourth BrainTransporter partnership — joining existing collaborations with Eisai, Bristol Myers Squibb and Novartis to advance brain-targeted biologics delivery
Subscribe now